Marina Biotech (MRNA) Commences Enrollment in START-FAP Cohort 2
Marina Biotech, Inc. (Nasdaq: MRNA), has announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508 will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston. The Company also noted that it has successfully transferred all GMP-related stability testing to a contract services organization.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
